DAS181治疗需要机械通气的副流感病毒肺部疾病造血干细胞移植患者。
DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.
作者信息
Chalkias S, Mackenzie M R, Gay C, Dooley C, Marty F M, Moss R B, Li T, Routh R L, Walsh S R, Tan C S
机构信息
Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Center for Virology and Vaccine Research, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
出版信息
Transpl Infect Dis. 2014 Feb;16(1):141-4. doi: 10.1111/tid.12177. Epub 2014 Jan 3.
Abstract
Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) patients. DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease.
摘要
副流感病毒感染是异基因造血干细胞移植（HSCT）患者发病和死亡的重要原因。DAS181是一种对流感和副流感病毒具有活性的新型抗病毒药物。据我们所知，我们报告了首例成功将DAS181用于患有严重副流感病毒性肺病的接受通气治疗的HSCT患者的2例病例。
相似文献
1
DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.DAS181治疗需要机械通气的副流感病毒肺部疾病造血干细胞移植患者。
Transpl Infect Dis. 2014 Feb;16(1):141-4. doi: 10.1111/tid.12177. Epub 2014 Jan 3.
2
DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center.单中心使用DAS181治疗造血干细胞移植受者的副流感病毒感染
Biol Blood Marrow Transplant. 2016 May;22(5):965-70. doi: 10.1016/j.bbmt.2016.02.011. Epub 2016 Feb 22.
3
Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients.DAS181治疗移植受者副流感3型感染的临床潜力。
Transpl Infect Dis. 2012 Aug;14(4):427-33. doi: 10.1111/j.1399-3062.2012.00718.x. Epub 2012 Feb 16.
4
Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.造血细胞移植受者及血液系统恶性肿瘤患者呼吸道病毒感染的管理
Clin Infect Dis. 2014 Nov 15;59 Suppl 5(Suppl 5):S344-51. doi: 10.1093/cid/ciu623.
5
DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.DAS181治疗肺移植受者的重症3型副流感病毒肺炎。
Transpl Infect Dis. 2013 Feb;15(1):E28-32. doi: 10.1111/tid.12045. Epub 2012 Dec 26.
6
DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study.DAS181 治疗免疫功能低下患者严重下呼吸道副流感病毒感染：一项 2 期随机、安慰剂对照研究。
Clin Infect Dis. 2021 Aug 2;73(3):e773-e781. doi: 10.1093/cid/ciab113.
7
Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children.DAS181成功治疗4例免疫功能低下儿童的副流感病毒呼吸道感染
J Pediatric Infect Dis Soc. 2015 Jun;4(2):114-8. doi: 10.1093/jpids/piu039. Epub 2014 May 14.
8
The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy.呼吸道合胞病毒、腺病毒、流感病毒和副流感病毒感染对接受干细胞移植、实体器官移植或癌症化疗的儿科患者的影响。
Pediatr Transplant. 2013 Mar;17(2):133-43. doi: 10.1111/petr.12022. Epub 2012 Dec 10.
9
Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome.造血干细胞移植后的副流感病毒感染：危险因素、对抗病毒治疗的反应及对移植结局的影响
Blood. 2001 Aug 1;98(3):573-8. doi: 10.1182/blood.v98.3.573.
10
Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation.造血干细胞移植后儿童前100天内呼吸道病毒感染导致的显著的移植相关死亡率。
Biol Blood Marrow Transplant. 2015 Oct;21(10):1802-7. doi: 10.1016/j.bbmt.2015.06.015. Epub 2015 Jun 25.
引用本文的文献
1
Viral infections in lung transplantation.肺移植中的病毒感染
J Thorac Dis. 2021 Nov;13(11):6673-6694. doi: 10.21037/jtd-2021-24.
2
A 48-Year-Old Previously Healthy Man Presenting with Acute Respiratory Distress Syndrome (ARDS), Negative Tests for SARS-CoV-2, and Positive Serology for Parainfluenza Virus Type 3 (PIV-3).一位 48 岁既往健康的男性，表现为急性呼吸窘迫综合征（ARDS），SARS-CoV-2 检测阴性，以及副流感病毒 3 型（PIV-3）血清学阳性。
Am J Case Rep. 2022 Jan 6;23:e934362. doi: 10.12659/AJCR.934362.
3
Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs.移植患者中的社区获得性呼吸道病毒：多样性、影响、未满足的临床需求。
Clin Microbiol Rev. 2019 Sep 11;32(4). doi: 10.1128/CMR.00042-19. Print 2019 Sep 18.
4
Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.造血系统恶性肿瘤患者与干细胞移植受者的呼吸道病毒感染
Infect Dis Clin North Am. 2019 Jun;33(2):523-544. doi: 10.1016/j.idc.2019.02.004. Epub 2019 Mar 30.
5
Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant.癌症患者或接受造血细胞移植患者的呼吸道病毒感染
Front Microbiol. 2018 Dec 12;9:3097. doi: 10.3389/fmicb.2018.03097. eCollection 2018.
6
Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention?副流感病毒3特异性T细胞：干预的契机？
J Infect Dis. 2017 Jul 15;216(2):147-149. doi: 10.1093/infdis/jix207.
7
Prophylactic Measures During Induction for Acute Myeloid Leukemia.急性髓系白血病诱导治疗期间的预防措施。
Curr Oncol Rep. 2017 Mar;19(3):18. doi: 10.1007/s11912-017-0574-9.
8
Antiviral Treatments.抗病毒治疗。
Clin Chest Med. 2017 Mar;38(1):139-153. doi: 10.1016/j.ccm.2016.11.008. Epub 2016 Dec 13.
9
Antiviral therapy for respiratory viral infections in immunocompromised patients.免疫功能低下患者呼吸道病毒感染的抗病毒治疗。
Expert Rev Anti Infect Ther. 2017 Apr;15(4):401-415. doi: 10.1080/14787210.2017.1279970. Epub 2017 Jan 16.
10
Non-invasive Imaging of Sendai Virus Infection in Pharmacologically Immunocompromised Mice: NK and T Cells, but not Neutrophils, Promote Viral Clearance after Therapy with Cyclophosphamide and Dexamethasone.仙台病毒感染的药理学免疫受损小鼠的无创成像：环磷酰胺和地塞米松治疗后，自然杀伤细胞和T细胞而非中性粒细胞促进病毒清除。
PLoS Pathog. 2016 Sep 2;12(9):e1005875. doi: 10.1371/journal.ppat.1005875. eCollection 2016 Sep.
本文引用的文献
1
The use of sialidase therapy for respiratory viral infections.唾液酸酶疗法在呼吸道病毒感染中的应用。
Antiviral Res. 2013 Jun;98(3):401-9. doi: 10.1016/j.antiviral.2013.04.012. Epub 2013 Apr 17.
2
DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.DAS181治疗肺移植受者的重症3型副流感病毒肺炎。
Transpl Infect Dis. 2013 Feb;15(1):E28-32. doi: 10.1111/tid.12045. Epub 2012 Dec 26.
3
A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.一项关于 DAS181 的 II 期研究，DAS181 是一种新型宿主导向抗病毒药物，用于治疗流感感染。
J Infect Dis. 2012 Dec 15;206(12):1844-51. doi: 10.1093/infdis/jis622. Epub 2012 Oct 8.
4
Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients.DAS181治疗移植受者副流感3型感染的临床潜力。
Transpl Infect Dis. 2012 Aug;14(4):427-33. doi: 10.1111/j.1399-3062.2012.00718.x. Epub 2012 Feb 16.
5
The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation.200 例白血病患者或造血干细胞移植受者副流感病毒感染的特征和结局。
Blood. 2012 Mar 22;119(12):2738-45; quiz 2969. doi: 10.1182/blood-2011-08-371112. Epub 2012 Jan 12.
6
Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation.同种异体干细胞移植后患者用 DAS181 治疗副流感 3 型感染。
Clin Infect Dis. 2011 Oct;53(7):e77-80. doi: 10.1093/cid/cir501. Epub 2011 Aug 31.
7
A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.一种重组唾液酸酶融合蛋白能有效抑制人副流感病毒在体外和体内的感染。
J Infect Dis. 2010 Jul 15;202(2):234-41. doi: 10.1086/653621.
8
End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease.用于测试高危严重和危及生命疾病患者的流感抗病毒治疗的终点。
J Infect Dis. 2010 Jun 1;201(11):1654-62. doi: 10.1086/652498.
9
Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease.副流感病毒进入细胞作为阻断儿童呼吸道疾病的靶点。
J Clin Invest. 2005 Jul;115(7):1688-98. doi: 10.1172/JCI25669.
10
Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome.造血干细胞移植后的副流感病毒感染：危险因素、对抗病毒治疗的反应及对移植结局的影响
Blood. 2001 Aug 1;98(3):573-8. doi: 10.1182/blood.v98.3.573.
Zotero 插件